Good morning, everyone, and how are you today? We are doing just fine, thank you, although running a bit behind schedule due to an uncooperative laptop that needs a version of Geritol, unfortunately. Nonetheless, we have diligently attempted to provide you with the latest assortment of interesting items as we prepare for another busy day. Hope all goes well and you conquer the world. And please do keep in touch. …

Insulin makers and pharmacy benefit managers sparred at a congressional hearing on Wednesday, blaming each other for escalating list prices of diabetes drugs and offering opposing policy prescriptions, STAT notes. But the blame game about the system frustrated both Democratic and GOP lawmakers of the House Energy and Commerce Committee oversight panel, who issued sharp warnings of reform, Modern Healthcare adds. And few clear solutions were offered by representatives, even as some sought drastic changes, according to Regulatory Focus.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy